Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 76

Sort by

Sort Order Select

Journal Articles

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

Blood (2023) 142 (Supplement 1): 3268.

https://doi.org/10.1182/blood-2023-173341

Published: 2023

Journal Articles

A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

Blood (2022) 140 (Supplement 1): 7013–7015.

https://doi.org/10.1182/blood-2022-157963

Published: 2022

Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Blood (2022) 140 (Supplement 1): 7007–7009.

https://doi.org/10.1182/blood-2022-159678

Published: 2022

Journal Articles

Post-CAR T-Cell Early Reconstitution of Peripheral T-Cell Subsets Is Heterogeneous and Independent of the Cell Therapy Outcome in High Grade B-Cell Lymphoma

Baptiste Le Calvez, Yannick Le Bris, Thomas Gastinne, Viviane Dubruille, Béatrice Mahé, Nicolas Blin, Anne Lok, Sophie Vantyghem, Clara Sortais, Cyrille Touzeau, Steven Le Gouill, Philippe Moreau, Patrice Chevallier, Marion Eveillard, Marie C Bene, Benoit Tessoulin

Blood (2022) 140 (Supplement 1): 12766–12767.

https://doi.org/10.1182/blood-2022-170113

Published: 2022

Journal Articles

Biological Differences between Axi-Cel and Tisa-Cel Products and Impacts on Outcomes in Lymphoma Patients

Benoit Tessoulin, Audrey Grain, Jocelyn Ollier, Thomas Gastinne, Viviane Dubruille, Béatrice Mahé, Nicolas Blin, Anne Lok, Sophie Vantyghem, Clara Sortais, Cyrille Touzeau, Philippe Moreau, Steven Le Gouill, Patrice Chevallier, Beatrice Clemenceau

Blood (2022) 140 (Supplement 1): 7411–7412.

https://doi.org/10.1182/blood-2022-163726

Published: 2022

Journal Articles

Combined Treatment with Ibrutinib and Anti-CD38 Monoclonal Antibody Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with TP53 Aberrations: Results of the Filo Phase II Study IDA53

Therese Aurran-Schleinitz, Cécile Tomowiak, Damien Roos-Weil, Emmanuelle Ferrant, Béatrice Mahé, Lysiane Molina, Loic Ysebaert, Luc Mathieu Fornecker, Anne-Sophie Michallet, Vincent Levy, Romain Guieze, Alain Delmer

Blood (2022) 140 (Supplement 1): 7030–7031.

https://doi.org/10.1182/blood-2022-163096

Published: 2022

Journal Articles

Antibody Response after One and/or Two Doses of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Patients Treated By CAR T-Cells Therapy

Blood (2021) 138 (Supplement 1): 254.

https://doi.org/10.1182/blood-2021-149476

Published: 2021

Journal Articles

Peripheral Levels of Monocytic Myeloid-Derived Suppressive Cells at Diagnosis Predict Survivals in AML Patients Eligible for Intensive Chemotherapy

Blood (2021) 138 (Supplement 1): 3465.

https://doi.org/10.1182/blood-2021-149405

Published: 2021

Journal Articles

Sars-Cov-2 T-Cell Response in Allogeneic Hematopoietic Stem Cell Recipients Following Two Doses of BNT162b2 Vaccine

Blood (2021) 138 (Supplement 1): 2895.

https://doi.org/10.1182/blood-2021-149139

Published: 2021

Journal Articles

A Prospective Phase 2 Study Testing High Dose Post-Transplant Cyclophosphamide As Sole Ghvd Prophylaxis after Matched Allotransplant Using Baltimore-Based Reduced-Intensity Conditioning Regimens and PBSC As Source of Graft

Patrice Chevallier, Amandine Le Bourgeois, Alice Garnier, Pierre Peterlin, Yannick Le Bris, Marion Eveillard, Béatrice Mahé, Viviane Dubruille, Nicolas Blin, Anne Lok, Cyrille Touzeau, Thomas Gastinne, Benoit Tessoulin, Maxime Jullien, Sophie Vantyghem, Philippe Moreau, Steven Le Gouill, Marie C Bene, Thierry Guillaume

Blood (2021) 138 (Supplement 1): 1812.

https://doi.org/10.1182/blood-2021-149534

Published: 2021

Journal Articles

Comparable Outcomes Among Adult Patients Allotransplanted for Myelodysplastic Syndrome Using Haploidentical, Matched Unrelated or Matched Sibling Donors: A Single-Center Study

Alice Garnier, Maxime Jullien, Thierry Guillaume, Pierre Peterlin, Amandine Le Bourgeois, Béatrice Mahé, Viviane Dubruille, Nicolas Blin, Cyrille Touzeau, Thomas Gastinne, Anne Lok, Benoit Tessoulin, Sophie Vantyghem, Marie C Bene, Philippe Moreau, Steven Le Gouill, Patrice Chevallier

Blood (2021) 138 (Supplement 1): 4914.

https://doi.org/10.1182/blood-2021-146826

Published: 2021

Journal Articles

Interest of a Third Dose of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Stem-Cells Recipients

Blood (2021) 138 (Supplement 1): 3908.

https://doi.org/10.1182/blood-2021-149178

Published: 2021

Journal Articles

Profound B-Cell Lymphopenia Is a Major Factor Predicting Poor Humoral Response after BNT162b2 mRNA Sars-Cov-2 Vaccines in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2021) 138 (Supplement 1): 3911.

https://doi.org/10.1182/blood-2021-150439

Published: 2021

Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

Blood (2021) 138 (Supplement 1): 641.

https://doi.org/10.1182/blood-2021-145624

Published: 2021

Journal Articles

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Blood (2021) 137 (8): 1019–1023.

https://doi.org/10.1182/blood.2020008164

Published: 2021

Includes: Supplemental data

Journal Articles

Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First - Line Treatment of Waldenstrom's Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial

Blood (2020) 136 (Supplement 1): 26.

https://doi.org/10.1182/blood-2020-140933

Published: 2020

Journal Articles

Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATE TM Study

Blood (2020) 136 (Supplement 1): 24–26.

https://doi.org/10.1182/blood-2020-134460

Published: 2020

Journal Articles

Absence of Influence of the Pre-Transplant Immune Status of Recipients on Survivals and Gvhd after Allogeneic Stem Cell Transplantation: A Retrospective Study of 195 Cases

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-136743

Published: 2020

Journal Articles

Open Label Non-Randomized Phase II Study Exploring «Chemo-Free » Treatment Association with Idelalisib + Obinutuzumab in Patients with Relapsed/Refractory (R/R) Waldenstrom's Macroglobulinemia (MW), a Filo Trial: Results of the Intermediary Analysis of the Induction Phase

Cecile Tomowiak, MD, Kristell Desseaux, Stéphanie Poulain, MD PhD, Charles Herbaux, MD, Aurore Perrot, MD PhD, Beatrice Mahe, MD, Pierre Morel, MD, Olivier Tournilhac, Stephane Lepretre, MD, Thérèse Aurran, MD, Bruno Villemagne, MD, Olivier Casasnovas, MD, Delphine Nollet, Brigitte Dreyfus, MD, Sylvie Chevret, MD PhD, Veronique Leblond, MD PhD

Blood (2019) 134 (Supplement_1): 346.

https://doi.org/10.1182/blood-2019-122826

Published: 2019

Journal Articles

Ptcy + ATG Compared to Ptcy Alone As Gvhd Prophylaxis for Peripheral Blood Stem Cells Allotransplant Is Associated with Significant Lower Incidence of Acute Gvhd without Increasing Relapse or Death By Infection

Patrice Chevallier, MD, Pierre Peterlin, Alice Garnier, MD, Amandine Le Bourgeois, MD, Beatrice Mahe, MD, Viviane Dubruille, MD, Nicolas Blin, MD, Cyrille Touzeau, MD, Thomas Gastinne, MD, Anne Lok, MD, Benoit Tessoulin, MD PhD, Yannick Le Bris, PharmD, Marie C Bene, PharmSci, PhD, Steven Le Gouill, MD PhD, Philippe Moreau, MD, Thierry Guillaume, MD PhD

Blood (2019) 134 (Supplement_1): 4528.

https://doi.org/10.1182/blood-2019-125787

Published: 2019

NARROW

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Post-CAR T-Cell Early Reconstitution of Peripheral T-Cell Subsets Is Heterogeneous and Independent of the Cell Therapy Outcome in High Grade B-Cell Lymphoma

Biological Differences between Axi-Cel and Tisa-Cel Products and Impacts on Outcomes in Lymphoma Patients

Combined Treatment with Ibrutinib and Anti-CD38 Monoclonal Antibody Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with TP53 Aberrations: Results of the Filo Phase II Study IDA53

Antibody Response after One and/or Two Doses of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Patients Treated By CAR T-Cells Therapy

Peripheral Levels of Monocytic Myeloid-Derived Suppressive Cells at Diagnosis Predict Survivals in AML Patients Eligible for Intensive Chemotherapy

Sars-Cov-2 T-Cell Response in Allogeneic Hematopoietic Stem Cell Recipients Following Two Doses of BNT162b2 Vaccine

A Prospective Phase 2 Study Testing High Dose Post-Transplant Cyclophosphamide As Sole Ghvd Prophylaxis after Matched Allotransplant Using Baltimore-Based Reduced-Intensity Conditioning Regimens and PBSC As Source of Graft

Comparable Outcomes Among Adult Patients Allotransplanted for Myelodysplastic Syndrome Using Haploidentical, Matched Unrelated or Matched Sibling Donors: A Single-Center Study

Interest of a Third Dose of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Stem-Cells Recipients

Profound B-Cell Lymphopenia Is a Major Factor Predicting Poor Humoral Response after BNT162b2 mRNA Sars-Cov-2 Vaccines in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First - Line Treatment of Waldenstrom's Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial

Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATE TM Study

Absence of Influence of the Pre-Transplant Immune Status of Recipients on Survivals and Gvhd after Allogeneic Stem Cell Transplantation: A Retrospective Study of 195 Cases

Open Label Non-Randomized Phase II Study Exploring «Chemo-Free » Treatment Association with Idelalisib + Obinutuzumab in Patients with Relapsed/Refractory (R/R) Waldenstrom's Macroglobulinemia (MW), a Filo Trial: Results of the Intermediary Analysis of the Induction Phase

Ptcy + ATG Compared to Ptcy Alone As Gvhd Prophylaxis for Peripheral Blood Stem Cells Allotransplant Is Associated with Significant Lower Incidence of Acute Gvhd without Increasing Relapse or Death By Infection

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only